2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Angiotensin-converting Enzyme (ACE)

Angiotensin-converting Enzyme (ACE)

Angiotensin-converting Enzyme (ACE)

Related Products

PDF 1.4 MB

Angiotensin-converting enzyme (ACE) indirectly increases blood pressure by causing blood vessels to constrict. ACE does that by converting angiotensin I to angiotensin II, which constricts the vessels. ACE, angiotensin I and angiotensin II are part of the renin-angiotensin system (RAS), which controls blood pressure by regulating the volume of fluids in the body. ACE is secreted in the lungs and kidneys by cells in the endothelium (inner layer) of blood vessels. It has two primary functions: ACE catalyses the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor in a substrate concentration-dependent manner. ACE degrades bradykinin, a potent vasodilator, and other vasoactive peptides. These two actions make ACE inhibition a goal in the treatment of conditions such as high blood pressure, heart failure, diabetic nephropathy, and type 2 diabetes mellitus. Inhibition of ACE (by ACE inhibitors) results in the decreased formation of angiotensin II and decreased metabolism of bradykinin, leading to systematic dilation of the arteries and veins and a decrease in arterial blood pressure.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P5827
    SBP1 peptide
    SBP1 peptide is a chemically synthesized 23-mer peptide fragment of the ACE2 PD α1 helix. SBP1 peptide associates with micromolar affinity to insect-derived SARS-CoV-2-RBD protein .
    SBP1 peptide
  • HY-129213
    CL-242817
    		Inhibitor
    CL-242817 is an orally available angiotensin converting enzyme (ACE) inhibitor. CL-242817 inhibits the conversion of angiotensin I to angiotensin II and has blood pressure lowering activity. CL-242817 can also improve Monocrotaline (HY-N0750) induced lung injury. CL-242817 can be used in the study of pulmonary fibrosis and hypertension-related diseases.
    CL-242817
  • HY-B0279S1
    Ramipril-d3
    Ramipril-d3 is the deuterium labeled Ramipril[1]. Ramipril (HOE-498) is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 5 nM.
    Ramipril-d<sub>3</sub>
  • HY-B0368A
    Captopril hydrochloride
    		Inhibitor
    Captopril (SQ 14225) hydrochloride, antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril hydrochloride is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM.
    Captopril hydrochloride
  • HY-A0116
    Trandolaprilate
    		Inhibitor
    Trandolaprilate is a potent angiotensin-converting enzyme (ACE) inhibitor. Trandolaprilate partially inhibits angiotensin-I-mediated c-fos induction. Trandolaprilate is main bioactive metabolite of Trandolapril. Trandolaprilate shows high lipophilicity.
    Trandolaprilate
  • HY-P4524
    FA-Phe-Phe
    FA-Phe-Phe is a furylacryloyl (fa)-amino acid derivative, targeting to Angiotensin-converting Enzyme (ACE). FA-Phe-Phe is also a specific substrate of Cathepsin A.
    FA-Phe-Phe
  • HY-A0116S
    Trandolaprilate-d5
    		Inhibitor
    Trandolaprilate-d5 is a deuterium labeled Trandolaprilate (Trandolaprilat). Trandolaprilate is an angiotensin-converting enzyme (ACE) inhibitor[1].
    Trandolaprilate-d<sub>5</sub>
  • HY-N8018
    Leucosceptoside A
    		Inhibitor
    Leucosceptoside A is a phenylethanoid glycoside with anti-hyperglycemic and anti-hypertensive activities. Leucosceptoside A shows inhibitory activity against α-glucosidase and PKCα (IC50 of 19.0 μM).
    Leucosceptoside A
  • HY-23093R
    L-Aspartyl-L-phenylalanine (Standard)
    		Inhibitor
    L-Aspartyl-L-phenylalanine (Standard) is the analytical standard of L-Aspartyl-L-phenylalanine. This product is intended for research and analytical applications. L-Aspartyl-L-phenylalanine is a metabolite of aspartame that can inhibit angiotensin converting enzyme (ACE) purified from rabbit lungs with a Ki of 11 μM.
    L-Aspartyl-L-phenylalanine (Standard)
  • HY-107352S
    Fosfenopril-d7
    Fosfenopril-d7 is deuterium labeled Fosfenopril.
    Fosfenopril-d<sub>7</sub>
  • HY-P2605
    Tuna AI
    		Inhibitor
    Tuna AI, an angiotensin-converting enzyme (ACE) inhibitor, exhibits IC50 values of 1 μM and 2 μM for ACEs from bovine and rabbit lungs, respectively.
    Tuna AI
  • HY-B0378AS
    Moexipril-d5 hydrochloride
    		Inhibitor
    Moexipril-d5 (hydrochloride) is deuterium labeled Moexipril (hydrochloride).
    Moexipril-d<sub>5</sub> hydrochloride
  • HY-A0116S1
    Trandolaprilate-d6
    Trandolaprilate-d6 is the deuterium labeled Trandolaprilate[1]. Trandolaprilate is a potent angiotensin-converting enzyme (ACE) inhibitor. Trandolaprilate partially inhibits angiotensin-I-mediated c-fos induction. Trandolaprilate is main bioactive metabolite of Trandolapril. Trandolaprilate shows high lipophilicity[2][3].
    Trandolaprilate-d<sub>6</sub>
  • HY-RS00150
    Ace Mouse Pre-designed siRNA Set A
    		Inhibitor

    Ace Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ace gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Ace Mouse Pre-designed siRNA Set A
    Ace Mouse Pre-designed siRNA Set A
  • HY-P3991
    Bradykinin potentiator C
    		Inhibitor
    Bradykinin potentiator C is a potent angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 7.1 μM for rabbit lung ACE. Bradykinin potentiator C is a postulated prototype of functional peptide.
    Bradykinin potentiator C
  • HY-126826
    Antibiotic K 4
    		Inhibitor
    Antibiotic K 4 is an inhibitor of angiotensin I converting enzyme (ACE) (Ki: 0.18 μM). Antibiotic K 4 inhibits pressor response to angiotensin I in rats.
    Antibiotic K 4
  • HY-13771R
    Ursodeoxycholic acid (Standard)
    		Inhibitor
    Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active.
    Ursodeoxycholic acid (Standard)
  • HY-P5913
    [Tyr6]-Angiotensin II
    [Tyr6]-Angiotensin II is a peptide fragment , and can bind to the angiotensin converting enzyme 2 .
    [Tyr6]-Angiotensin II
  • HY-14923
    Ilepatril
    		Inhibitor
    Ilepatril, a dual inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase, has inhibitory effects in the type 2 diabetic nephropathy model in obese Zucker diabetic fatty (ZDF) rats. Ilepatril significantly reduced albuminuria in a dose-dependent manner and may be a strategy distinct from metabolic control to inhibit type 2 diabetic nephropathy.
    Ilepatril
  • HY-B0592A
    Trandolapril hydrochloride
    		Inhibitor
    Trandolapril (RU44570) hydrochloride is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolapril hydrochlorideat. Trandolapril hydrochloride is an orally active angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI).
    Trandolapril hydrochloride
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity